{
  "id": "5896e4d478275d0c4a000015",
  "type": "yesno",
  "question": "Is golimumab effective for ulcerative colitis?",
  "ideal_answer": "Yes. Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24955447",
    "http://www.ncbi.nlm.nih.gov/pubmed/27494322",
    "http://www.ncbi.nlm.nih.gov/pubmed/24502344",
    "http://www.ncbi.nlm.nih.gov/pubmed/26907481",
    "http://www.ncbi.nlm.nih.gov/pubmed/25609972",
    "http://www.ncbi.nlm.nih.gov/pubmed/24285003",
    "http://www.ncbi.nlm.nih.gov/pubmed/26738756",
    "http://www.ncbi.nlm.nih.gov/pubmed/24160948",
    "http://www.ncbi.nlm.nih.gov/pubmed/24774504",
    "http://www.ncbi.nlm.nih.gov/pubmed/18683105",
    "http://www.ncbi.nlm.nih.gov/pubmed/27498886",
    "http://www.ncbi.nlm.nih.gov/pubmed/25876561",
    "http://www.ncbi.nlm.nih.gov/pubmed/23344099",
    "http://www.ncbi.nlm.nih.gov/pubmed/23735746",
    "http://www.ncbi.nlm.nih.gov/pubmed/26600980",
    "http://www.ncbi.nlm.nih.gov/pubmed/24842416",
    "http://www.ncbi.nlm.nih.gov/pubmed/24506179",
    "http://www.ncbi.nlm.nih.gov/pubmed/26786341",
    "http://www.ncbi.nlm.nih.gov/pubmed/27440869",
    "http://www.ncbi.nlm.nih.gov/pubmed/25729432",
    "http://www.ncbi.nlm.nih.gov/pubmed/23897288",
    "http://www.ncbi.nlm.nih.gov/pubmed/25817087",
    "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
    "http://www.ncbi.nlm.nih.gov/pubmed/25294262",
    "http://www.ncbi.nlm.nih.gov/pubmed/23770005",
    "http://www.ncbi.nlm.nih.gov/pubmed/26893582",
    "http://www.ncbi.nlm.nih.gov/pubmed/27695502",
    "http://www.ncbi.nlm.nih.gov/pubmed/27723166"
  ],
  "snippets": [
    {
      "text": "Initial experience with golimumab in clinical practice for ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti-TNF ulcerative colitis patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "OBJECTIVE: The objective of this study was to assess the cost-effectiveness of induction and maintenance treatment up to 1 year of ulcerative colitis with golimumab/standard care and standard care alone in Poland.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The biologic treatment of ulcerative colitis patients with golimumab/standard care is more effective but also more costly compared with standard care alone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long-term remission of IBD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723166",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27699641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: No significant differences in efficacy in the maintenance phase between infliximab and golimumab or adalimumab were revealed. Infliximab proved to be more effective than adalimumab but of similar efficacy to that of golimumab in the induction phase.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27695502",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this review, we will provide a detailed discussion of the three tumor necrosis factor-alpha (TNF-\u03b1) inhibitors currently approved for treatment of ulcerative colitis: infliximab, adalimumab, and golimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25609972",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Golimumab for moderately to severely active ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23770005",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735746",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-\u03b1 (TNF\u03b1), was evaluated as maintenance therapy in TNF\u03b1 antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy.We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23770005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23897288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The purpose of this review was to describe the management of ulcerative colitis with emphasis on the use of anti-tumor necrosis factor (TNF) agents.Recent research has shown that new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and maintenance of remission in patients with extensive ulcerative colitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The required sample sizes for direct head-to-head trials between infliximab and adalimumab for induction and maintenance are 174 and 204 subjects respectively.This study demonstrates that, compared to placebo, infliximab, adalimumab and golimumab are all effective for the induction and maintenance of remission in ulcerative colitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The biosimilar of infliximab is as effective and as safe as its originator in rheumatologic conditions, while a new anti-TNF agent, namely golimumab, has been recently approved for refractory ulcerative colitis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25729432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated subcutaneous golimumab induction therapy in TNF-\u03b1 antagonist-na\u00efve patients with moderate-to-severe UC despite conventional treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The purpose of this review was to describe the management of ulcerative colitis with emphasis on the use of anti-tumor necrosis factor (TNF) agents.Recent research has shown that new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and maintenance of remission in patients with extensive ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The biosimilar of infliximab is as effective and as safe as its originator in rheumatologic conditions, while a new anti-TNF agent, namely golimumab, has been recently approved for refractory ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25729432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The incremental cost-utility ratio of golimumab/standard care compared to the standard care alone is estimated to be 391,252 PLN/QALY gained (93,155 \u20ac/QALYG) from public payer perspective and 374,377 PLN/QALY gained (89,137 \u20ac/QALYG) from social perspective.The biologic treatment of ulcerative colitis patients with golimumab/standard care is more effective but also more costly compared with standard care alone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27494322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The required sample sizes for direct head-to-head trials between infliximab and adalimumab for induction and maintenance are 174 and 204 subjects respectively.This study demonstrates that, compared to placebo, infliximab, adalimumab and golimumab are all effective for the induction and maintenance of remission in ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, 2 new antibodies have been approved: golimumab is a new option for ulcerative colitis and with another more selective mechanism of action; vedolizumab could be useful for ulcerative colitis as well as Crohn's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25294262",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The present review summarizes the literature on the role of golimumab, a new anti TNF agent, in ulcerative colitis.Literature search was done on PubMed using the search terms 'golimumab' AND 'ulcerative colitis' from inception till March 2016.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The aim of this systematic review was to evaluate the efficacy and safety of biological agents (vedolizumab, abatacept, visilizumab, golimumab) in patients with active moderate to severe ulcerative colitis.This paper was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND & AIMS: Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-\u00e1 (TNF\u00e1), was evaluated as maintenance therapy in TNF\u00e1 antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy.METHODS: We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, eg, PURSUIT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23770005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND & AIMS: Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -\u00e1, for treatment of ulcerative colitis (UC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study demonstrates that, compared to placebo, infliximab, adalimumab and golimumab are all effective for the induction and maintenance of remission in ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vedolizumab and golimumab occurred more effective, and comparably as safe as placebo in patients with active moderate to severe ulcerative colitis increasing the number of available therapeutic options..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent research has shown that new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and maintenance of remission in patients with extensive ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24285003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Golimumab for moderately to severely active ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Initial experience with golimumab in clinical practice for ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26786341",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Golimumab was found to be effective and safe in inducing and maintaining clinical remission, clinical response and mucosal healing in patients with UC in the two registration trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27498886",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Golimumab Therapy in Ulcerative Colitis].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26907481",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Golimumab: clinical update on its use for ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25876561",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This review will focus on golimumab therapy in ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26907481",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-severe ulcerative colitis [UC] from the Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment [PURSUIT] studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27440869",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003093",
    "http://www.disease-ontology.org/api/metadata/DOID:8577",
    "http://www.biosemantics.org/jochem#4002191"
  ],
  "exact_answer": "Yes"
}